Matthew D. Email & Phone Number

United States

Rockville, Maryland, United States

• Leader in Cellphire’s R&D team focused on bringing cell-based therapeutics to market.• Conceptualize and develop bioassays to detect and secure function of biological agents to support clinical trial applications.• Managed and designed pre-clinical animal studies in murine, rabbit and primates at multiple CROs to establish IND enabling data.• Troubleshoot and change product release assays to ensure proper product targeting for the Quality control department and document changes in SOPs.• Set-up external collaborations, authored work plans and final reports.• Presented at American Association of Hematology Lyophilized Human Platelets Restore Hemostasis in the Presence of the P2Y12 Inhibitors Cangrelor, Ticagrelor and Clopidogrel and International Society on Thrombosis and Haemostasis Lyophilized human platelets support thrombosis unlike normal platelets in the presence of GPIIb/IIIa antagonists.

Cambridge, Massachusetts

Develop point of care diagnostics using the proprietary rHEALTH hand held platform. Producing diagnostic assays to allow doctor office use or home blood cell counts; white blood cell counts, platelet, CBCs with differential. Along side development of fertility testing and biomarkers from blood plasma and serum.

Cambridge Ma

• Diagnostics for All develops an array of diagnostic test targeted at underserved markets throughout the world. These diagnostic tests are used to better the quality of life of the people in the developing countries• Head the team charged with developing a lateral flow diagnostic assay (akin to a pregnancy test) to better detect estrus in dairy cattle. The test will be first to market to utilize unprocessed whole blood samples. The test detects the presence or absence of the hormone progesterone through competitive antibody binding on a gold particle. The goal is to increase birth rate in cattle hence increasing the milk production.• My team designed, assembled, verified in laboratory for cut-point, accuracy, reproducible, repeatability and stability of the device. Subsequently I lead the infield verification of the device.• The manufacturer documentation and method transfer is currently underway completing the tenure of DFA.

Lexington, Ma

• Lead a team of junior scientist to successfully develop multiple immunoassay projects per year• Developed and managed project plans under strict timelines while executing laboratory experimentation and communication between scientist, sale, marketing and customers.• These projects have included the detection and analysis of low affinity antibodies to drug (ADA) conjugates to support PK, measuring low abundant biomarker (cytokines), cell based assays to measuring receptor activation and or drug modulation (kinase phosphorylation/sulfenylation), antibody detection and quantitation for autoimmune disease (rheumatoid factor) and vaccine titers. • Publication this year include development of cell-based drug screening assay by measuring tyrosine kinase receptor activation (Analytical Biochemistry), a ligand binding assay to support PK (American Association of Pharmacuetical Sciences) and recently submitted manuscript on an assay to detect low affinity antibodies to drug conjugates (American Association of Pharmaceutical Sciences).

Lexington, Massachusetts

• Managed international collaborations with top institutes in the US, Europe and Asia. • Supervise the internal development and validation of cell-based and immunoassays for commercialization on the AMMP platform with comparison data on industrial standard technologies like ELISA, Western blots, Flow Cytometry, MSD and Biacore. Biomarker analysis was completed from a multitude of sample types like whole tissue, cell lysates, serum, plasma and urine. • Developed novel uses of the technology to detect whole mammalian cells, e-coli and salmonella; competition assays of PK analysis, antibody and phage display target screening with apparent kD analysis and small molecule target binding.

• Direct the efforts of a team of junior scientist to develop immunoassays. These assays have included panels of kinase targets including pAKT, pERK, pp38, pJNK and pMEK for analysis in cell culture and in-vivo tissue. Additionally have developed assays to monitor kinase interactions i.e. MEK-ERK association and dissociation for drug development and as biomarker analysis.• Work closely with academic and industrial collaborators to support their application’s efforts. These applications have included biomarkers for toxicology, inflammation and drug targeting. Recently completing a collaboration with the National Cancer Institute to develop oncology biomarker assays for serum, tissue samples and cell culture samples. • Collaborated with the Sales and Marketing department to present talks throughout the country at scientific meetings and tradeshows. Additionally worked closely with senior management to focus the company’s direction.

Boston, Ma

Completed my doctoral studies in pharmacology. Thesis entitled the 'Effect of dopamine and age on the neuronal co-expression of D1 and D2 dopamine receptors in the striatum'. Utilizing the pharmacological in-vivo rat model of Parkinson's disease and immunohistochemistry techniques showed that dopamine receptors change their expression pattern post dopamine loss. The area of the adolescent rat's brain known as the substantia nigra was surgically lesioned and allowed to deteriorate over time. At multiple time points post lesioning the brain was surgically removed for immunohistological analyzed. The progression of the changes in dopamine receptors was followed in multiple brain section across the length of the brain. Each brain section was triple immunohistologically stained by antibodies to the D1, D2 receptors and a nuclear marker. The expression pattern was quantitated by Bioquant software analysis. The conclusion revealing that as the loss of dopamine progressed the receptors for dopamine modified their expression. Modified dopamine receptors expression would mean that externally dosed L-dopa could have differential effects based on when it was begun in the progression of the disease.

Boston, Massachusetts, United States

• Therapeutic antibody development which including designed antigenic targets, hybridoma production.• Screen monoclonal and polyclonal antibodies targeting by protein, cellular targets using ELISA, and FACS• Designed and implemented cell-based proliferation assay to test therapeutic drug candidates to kill cancer cells by FACS, microvessel growth assays

Andover Ma

▪Bioanalytical sciences department senior member ▪Developed pharmacodynamic FACS assay for IND enabling studies (primate)▪Collaborated across pre-clinical development groups to coordinate efforts in assay development for clinical and pre-clinical cell based and solid state assays•Patented on clinical assay developed to screen patient sera for neutralizing and non-neutralizing antibodies against BMP-2▪Brought in-house new technologies – Confocal scanning laser microscopy

Doctorate, Pharmacology

▪Thesis work in the pharmacology of dopamine receptors in the animal model of Parkinson’s disease.

Bachelors Of Science, Biology

Major in Biology with a minor in Chemistry